ADIPOQ and Other metabolic disease: Indeed, in recent studies higher adiponectin was associated with a significant increase in cardiovascular disease mortality in patients with metabolic diseases, and suggest that patients with low IRAK3 may not benefit from treatment with adiponectin or adiponectin mimetics [27], [28].